Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Leukemia|December 1, 1995
CD49f (alpha 6 integrin) and CD66a (BGP) are specifically induced by retinoids during human monocytic differentiationJ Botling, F Oberg, K Nilsson
Journal of Immunology (Baltimore, Md. : 1950)|April 15, 1993
Functional antagonism between vitamin D3 and retinoic acid in the regulation of CD14 and CD23 expression during monocytic differentiation of U-937 cellsF Oberg, J Botling, K Nilsson
International Journal of Cancer|July 15, 1994
Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoproteinJ Botling, G Liminga, R Larsson, et al.
Thrombosis Research|November 15, 1997
Tissue factor expression in human monocytic cell linesT Tenno, J Botling, F Oberg, et al.
The Journal of Biological Chemistry|April 4, 1997
Retinoic acid receptor/retinoid X receptor heterodimers can be activated through both subunits providing a basis for synergistic transactivation and cellular differentiationJ Botling, D S Castro, F Oberg, et al.
Leukemia|June 24, 2000
The role of RAR and RXR activation in retinoid-induced tissue factor suppressionT Tenno, J Botling, F Oberg, et al.
Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research|September 1, 1996
Vitamin D3- and retinoic acid-induced monocytic differentiation: interactions between the endogenous vitamin D3 receptor, retinoic acid receptors, and retinoid X receptors in U-937 cellsJ Botling, F Oberg, H Törmä, et al.
Langenbeck'S Archives of Surgery|May 7, 2009
Long-term effects of surgical correction of adrenal hyperplasia and adenoma causing primary aldosteronismJ Hennings, S Andreasson, J Botling, et al.
British Journal of Cancer|September 1, 1996
Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistanceS Dhar, P Nygren, K Csoka, et al.
Heliyon|December 11, 2023
Utilizing CD44v6 and V600EBRAF-mutation for in vitro targeted combination therapy of thyroid carcinomasA C L Mortensen, J Imgenberg-Kreuz, D Spiegelberg, et al.
Pageof 2